Puma Biotechnology Inc. (PBYI) said it will delay filing for U.S. regulatory approval of its experimental breast cancer treatment by as much as a year. The company’s shares fell 15 percent to $192.36 at 9:36 a.m. in New York, the most since June. The drugmaker announced yesterday that it would apply for Food and Drug [...]